{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:43:04Z","timestamp":1794278584072,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.adro.2022.101112","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T02:18:06Z","timestamp":1666318686000},"page":"101112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Definitions of \u201cCure\u201d After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-3190","authenticated-orcid":false,"given":"Andreas","family":"Boehle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Zywietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Robrahn-Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inke R.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Lusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.101112_bib0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0002","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.101112_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American brachytherapy society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101112_bib0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2010.08.045","article-title":"American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer","volume":"79","author":"Rosenthal","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101112_bib0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.brachy.2018.08.008","article-title":"Using a surgical prostate-specific antigen threshold of >0.2 ng\/ml to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ascende-rt randomized control trial","volume":"17","author":"Morris","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101112_bib0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.brachy.2018.05.011","article-title":"Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng\/ml","volume":"17","author":"Taussky","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101112_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brachy.2020.07.006","article-title":"Time to achieve a prostate-specific antigen nadir of \u22640.2 ng\/ml and related factors after permanent prostate brachytherapy","volume":"20","author":"Soyano","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101112_bib0008","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2022.101112_bib0009","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.eururo.2021.08.026","article-title":"Re: A biochemical definition of cure after brachytherapy for prostate cancer","volume":"80","author":"Alan McNeill","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0010","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00345-019-02649-2","article-title":"Combined-modality (125)J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: Report of outcomes and side-effects","volume":"37","author":"Boehle","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2005.06.001","article-title":"EAU guidelines on prostate cancer","volume":"48","author":"Aus","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0012","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0013","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.6004\/jnccn.2015.0181","article-title":"NCCN clinical practice guidelines prostate cancer early detection, version 2.2015","volume":"13","author":"Carroll","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2022.101112_bib0014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0360-3016(95)00521-Y","article-title":"A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation","volume":"32","author":"Stock","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101112_bib0015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0302-2838(02)00018-0","article-title":"Importance of post-implant dosimetry in permanent prostate brachytherapy","volume":"41","author":"Stock","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0016","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eururo.2019.09.027","article-title":"Predicting prostate cancer death with different pretreatment risk stratification tools: A head-to-head comparison in a nationwide cohort study","volume":"77","author":"Zelic","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brachy.2019.09.001","article-title":"Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy","volume":"19","author":"Boehle","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101112_bib0018","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2021.04.035","article-title":"Patterns of clinical progression in radiorecurrent high-risk prostate cancer","volume":"80","author":"Philipson","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0019","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/sim.2677","article-title":"Confidence intervals for predictive values with an emphasis to case-control studies","volume":"26","author":"Mercaldo","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.adro.2022.101112_bib0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0021","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2021.07.025","article-title":"Functional and oncological outcomes after open versus robot-assisted laparoscopic radical prostatectomy for localised prostate cancer: 8-year follow-up","volume":"80","author":"Lantz","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0022","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1111\/bju.13903","article-title":"Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer","volume":"120","author":"Zumsteg","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2022.101112_bib0023","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","article-title":"Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens","volume":"69","author":"Sauter","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0024","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1007\/s00345-021-03717-2","article-title":"Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: Implications for active surveillance","volume":"39","author":"Meissner","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.adro.2022.101112_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2013.10.010","article-title":"Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival","volume":"88","author":"Lo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101112_bib0026","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.brachy.2018.08.018","article-title":"Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy","volume":"17","author":"Niwa","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101112_bib0027","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: An aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101112_bib0028","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422002184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422002184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:42:26Z","timestamp":1762530146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422002184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2452109422002184"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.101112","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definitions of \u201cCure\u201d After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.101112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101112"}}